Israel
· Delayed Price · Currency is ILS · Price in ILAEndymed Statistics
Total Valuation
Endymed has a market cap or net worth of ILS 33.85 million. The enterprise value is 10.45 million.
| Market Cap | 33.85M |
| Enterprise Value | 10.45M |
Important Dates
The next estimated earnings date is Thursday, November 21, 2024.
| Earnings Date | Nov 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Endymed has 13.76 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 13.76M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | -2.95% |
| Owned by Insiders (%) | 9.45% |
| Owned by Institutions (%) | 0.66% |
| Float | 5.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| PB Ratio | 0.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.32 |
| EV / Sales | 0.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.85 |
Financial Position
The company has a current ratio of 4.49, with a Debt / Equity ratio of 7.80.
| Current Ratio | 4.49 |
| Quick Ratio | 2.75 |
| Debt / Equity | 7.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.35 |
| Interest Coverage | -14.75 |
Financial Efficiency
Return on equity (ROE) is -5.53% and return on invested capital (ROIC) is -4.15%.
| Return on Equity (ROE) | -5.53% |
| Return on Assets (ROA) | -3.28% |
| Return on Capital (ROIC) | -4.15% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | -68,345 |
| Employee Count | 46 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.37% in the last 52 weeks. The beta is -0.26, so Endymed's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | -34.37% |
| 50-Day Moving Average | 274.10 |
| 200-Day Moving Average | 309.12 |
| Relative Strength Index (RSI) | 27.88 |
| Average Volume (20 Days) | 1,815 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Endymed had revenue of ILS 73.81 million and -3.14 million in losses. Loss per share was -0.23.
| Revenue | 73.81M |
| Gross Profit | 36.25M |
| Operating Income | -4.06M |
| Pretax Income | -3.77M |
| Net Income | -3.14M |
| EBITDA | -3.54M |
| EBIT | -4.06M |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 27.71 million in cash and 4.31 million in debt, giving a net cash position of 23.41 million or 1.70 per share.
| Cash & Cash Equivalents | 27.71M |
| Total Debt | 4.31M |
| Net Cash | 23.41M |
| Net Cash Per Share | 1.70 |
| Equity (Book Value) | 55.24M |
| Book Value Per Share | 4.11 |
| Working Capital | 48.08M |
Cash Flow
In the last 12 months, operating cash flow was -12.07 million and capital expenditures -282,383, giving a free cash flow of -12.36 million.
| Operating Cash Flow | -12.07M |
| Capital Expenditures | -282,383 |
| Free Cash Flow | -12.36M |
| FCF Per Share | -0.90 |
Margins
Gross margin is 49.11%, with operating and profit margins of -5.49% and -4.26%.
| Gross Margin | 49.11% |
| Operating Margin | -5.49% |
| Pretax Margin | -5.11% |
| Profit Margin | -4.26% |
| EBITDA Margin | -4.79% |
| EBIT Margin | -5.49% |
| FCF Margin | -16.74% |
Dividends & Yields
Endymed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -9.23% |
| FCF Yield | -36.50% |
Stock Splits
The last stock split was on January 28, 2018. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 28, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.05 |